Cencora, Inc.

Our two largest customers, Walgreens Boots Alliance, Inc. ("WBA") and Evernorth Health Services (formerly Express Scripts, Inc.), accounted for approximately 26% and approximately 13%, respectively, of revenue in fiscal 2024.

Our two largest customers, Walgreens Boots Alliance, Inc. ("WBA") and Express Scripts, Inc. ("Express Scripts"), accounted for approximately 26% and approximately 14%, respectively, of revenue in the fiscal year ended September 30, 2023.

Our two largest customers, Walgreens Boots Alliance, Inc. ("WBA") and Express Scripts, Inc. ("Express Scripts"), accounted for approximately 27% and approximately 13%, respectively, of revenue in the fiscal year ended September 30, 2022.

Our two largest customers, WBA and Express Scripts, Inc. ("Express Scripts"), accounted for approximately 31% and approximately 12%, respectively, of revenue in the fiscal year ended September 30, 2021.

Cencora 45 % 40 % 44 % 33 %

For continuing operations, gross product revenues by significant customers as a percentage of total gross product revenues were as follows: Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 McKesson Corporation 42% 44% 40% 45%Cencora, Inc. 40% 39% 41% 37%Cardinal Health, Inc. 16% 15% 18% 17% Product Sales Discounts and AllowancesThe total provision related to sales made in the prior period was $(13.0) million and $(8.7) million for the three months ended June 30, 2026 and 2025, respectively.

The Company’s net revenue from continuing operations was as follows: Three Months Ended March 31, (in thousands) 2026 2025LOQTORZI $ 11,803 $ 7,348Other revenue 507 251 Total net revenue $ 12,310 $ 7,599 For continuing operations, gross product revenues by significant Customers as a percentage of total gross product revenues were as follows: Three Months Ended March 31, 2026 2025 McKesson Corporation 37% 46%Cencora, Inc. 42% 33%Cardinal Health, Inc. 20% 20% Product Sales Discounts and AllowancesChargebacks and discounts for prompt payment are recorded as a reduction in trade receivables, and the remaining reserve balances are classified as current liabilities on the condensed consolidated balance sheets.In connection with the sales of the CIMERLI ophthalmology franchise and the YUSIMRY franchise in 2024 and the UDENYCA franchise in 2025, the Company retained and continued to be responsible for sales discounts and allowance liabilities incurred prior to March 1, 2024 for CIMERLI, June 26, 2024 for YUSIMRY and April 11, 2025 for UDENYCA.

Cencora, Inc. 36 % 43 %

AmerisourceBergen Corporation (1) 39 % 35 %

AmerisourceBergen Corporation (1) 36 % 35 % 39 % 36 %

AmerisourceBergen Corporation (1) 40 % 39 % 40 % 40 %

AmerisourceBergen Corporation (1) 42 % 38 %

AmerisourceBergen Corporation (1) 39 % 35 % 40 % 36 %

Cencora, Inc. 29 % 29 % 29 %

Cencora, Inc. 29 % 29 % 25 %

Cencora, Inc. (formerly known an AmerisourceBergen Corporation) 29 % 25 % 25 %

Cencora, Inc., previously known as AmerisourceBergen Corporation (1) 29 % 35 % 36 %

Cencora 30 % 28 % 28 % 23 % 25 % 22 %

Cencora 25 % 28 % 21 % 21 %

Cencora 22 % 20 % 20 %

Cencora 30 % 23 % 22 % 21 % 22 % 20 %

Cencora 27 % 23 % 23 % 20 % 22 % 20 %

Cencora 25 % 23 % 21 % 20 %

Cencora 28 % 16 % 21 % 17 % 20 % 20 %

Cencora 23 % 16 % 20 % 21 % 20 % 22 %

Cencora 13 % 16 % 20 % 24 %

Cencora Inc. 20 % 20 % 23 %

AmerisourceBergen 9 % 16 % 17 % 23 % 20 % 23 %

AmerisourceBergen 13 % 16 % 21 % 24 % 22 % 23 %

AmerisourceBergen 16 % 16 % 24 % 22 %

Cencora Inc. 20 % 23 % 24 %

AmerisourceBergen 14 % 13 % 23 % 25 % 23 % 24 %

AmerisourceBergen 17 % 13 % 24 % 23 % 23 % 24 %

AmerisourceBergen 13 % 13 % 22 % 25 %

AmerisourceBergen Corporation 23 % 24 % 23 %

AmerisourceBergen Corporation 24 % 23 % 24 %

AmerisourceBergen — — 25 %

AmerisourceBergen Corporation 22 % 20 % 21 % 22 %

AmerisourceBergen Corporation 26 % 13 %

Cencora, Inc. (“Cencora”) 21 % 21 % 22 %

Cencora, Inc. (formerly known as AmerisourceBergen Corporation) 19 % 18 % 19 % 17 %

AmerisourceBergen Corporation 19 % 17 % 18 % 18 %

AmerisourceBergen Corporation 18 % 19 %

Cencora, Inc. 18 % 19 % 18 %

Cencora, Inc. (formerly known as AmerisourceBergen Corporation) 19 % 18 % 23 %

AmerisourceBergen Corporation 18 % 25 % 17 % 24 %

AmerisourceBergen Corporation 17 % 21 % 18 % 24 %

AmerisourceBergen Corporation 19 % 27 %

AmerisourceBergen Corporation 18 % 23 % 27 %

AmerisourceBergen Corporation 25 % 30 % 24 % 25 %

AmerisourceBergen Corporation 21 % 21 % 24 % 21 %

AmerisourceBergen Corporation 27 % 22 %

AmerisourceBergen Corporation 23 % 27 % 21 %

AmerisourceBergen Corporation 30 % 21 % 25 % 21 %

AmerisourceBergen Corp. 21 % 20 % 21 % 20 %

AmerisourceBergen Corp. 22 % 21 %

AmerisourceBergen Corporation 27 % 21 % 20 %

AmerisourceBergen Corp. 21 % 20 % 21 % 20 %

AmerisourceBergen Corp. 20 % 20 % 20 % 20 %

AmerisourceBergen Corp. 21 % 21 %

AmerisourceBergen Corp. 21 % 20 % 20 %

AmerisourceBergen Corp. 20 % 21 % 20 % 20 %

AmerisourceBergen Corp. 20 % 20 % 20 % 20 %

AmerisourceBergen Corp. 21 % 20 %

AmerisourceBergen Corp. 20 % 20 % 18 %

Cencora, Inc. 21 % 12 % 22 % 15 %

Cencora, Inc. 23 % 19 % 17 % 20 %

Cencora, Inc. 12 % 20 % 15 % 21 %

Cencora, Inc. * 19 % 21 %

Cencora, Inc., formerly known as AmerisourceBergen Drug Corporation 21 % 15 %

For the year ended December 31, 2025, sales to the Company’s three largest product distributors, ASD Specialty Healthcare (Cencora), McKesson and Shanghai Pharmaceutical represented approximately 18.5%, 17.5% and 10.1% of product revenue, respectively, and collectively, represented approximately 37.1% of trade accounts receivable as of December 31, 2025.

For the year ended December 31, 2024, sales to the Company’s three largest product distributors, ASD Specialty Healthcare (Cencora), McKesson and Shanghai Pharmaceutical represented approximately 18.0%, 16.9% and 11.1% of product revenue, respectively, and collectively, represented approximately 51.0% of trade accounts receivable as of December 31, 2024.

For the year ended December 31, 2023, sales to the Company’s four largest product distributors, Sinopharm, Shanghai Pharmaceutical, ASD Specialty Healthcare and China Resources represented approximately 16.0%, 14.2%, 12.4% and 11.4% of product revenue, respectively, and collectively, represented approximately 53.2% of trade accounts receivable as of December 31, 2023.

For the year ended December 31, 2023, sales to the Company’s four largest product distributors, ASD Specialty Healthcare, McKesson, Sinopharm, and Shanghai Pharmaceutical, represented approximately 16.0%, 14.2%, 12.4% and 11.4% of product revenue, respectively, and collectively, represented approximately 53.2% of trade accounts receivable as of December 31, 2023.

Cencora Inc. 18% 19% 19%

Cencora Inc. 19% 19% 18%

Cencora Inc. (formerly AmerisourceBergen Corporation) 19% 18% 18%

Sales to Western Wellness Solutions LLC, McKesson Corporation, Cardinal Health, Inc., and AmerisourceBergen accounted for 42.1%, 21.2%, 18.3% and 17.0% of total gross sales, respectively, for the year ended December 31, 2021.

Cencora, Inc. 16.0 % 20.5 % 16.5 % 19.5 %

Cencora, Inc. 17.2 % 18.2 %

Cencora (formerly AmerisourceBergen Drug Corporation) 17.3 % 16.4 % 19.1 %

Cencora (formerly AmerisourceBergen Drug Corporation) 17.3 % 13.8 % 18.6 % 15.9 %

Cencora (formerly AmerisourceBergen Drug Corporation) 20.5 % 15.3 % 19.5 % 17.7 %

Cencora (formerly AmerisourceBergen Drug Corporation) 18.2 % 21.6 %

AmerisourceBergen Drug Corporation 14.0 % 21.2 % 15.1 % 21.3 %

AmerisourceBergen Drug Corporation 14.2 % 21.1 % 15.8 % 21.3 %

AmerisourceBergen Drug Corporation 18.3 % 21.6 %

Cencora 16.4 % 19.1 % 11.1 %

AmerisourceBergen Drug Corporation 21.2 % 26.4 % 21.3 % 28.9 %

AmerisourceBergen Drug Corporation 21.1 % 40.2 % 21.3 % 35.1 %

Sales to Cardinal Health, AmerisourceBergen Drug Corporation, and McKesson Corporation made up 22.2%, 21.6%, and 20.8%, respectively, of our product sales, net during the three months ended March 31, 2023.

Cencora, Inc. 16 % 17 % 12 %

Cencora, Inc. 17 % 12 % 5 %

The following summarizes revenue, as a percentage of total revenues, for our three largest U.S. wholesaler customers: Year Ended December 31,202220212020McKesson, Inc.8 %9 %16 %AmerisourceBergen Corporation5 %7 %14 %Cardinal Health, Inc.4 %5 %10 %

The following summarizes revenue, as a percentage of total revenues, for our three largest U.S. wholesaler customers: Year Ended December 31,202120202019McKesson, Inc.9 %16 %15 %AmerisourceBergen Corporation7 %14 %11 %Cardinal Health, Inc.5 %10 %9 %

The following summarizes revenue, as a percentage of total revenues, for our three largest U.S. wholesaler customers: Year Ended December 31,202020192018McKesson, Inc.16 %15 %13 %AmerisourceBergen Corporation13 %11 %8 %Cardinal Health, Inc.10 %9 %8 %

AmerisourceBergen 12 % 11 % 11 %

AmerisourceBergen Corp. 11.4 % 10.0 % 8.5 % 14.4 % 9.7 %

AmerisourceBergen Corp. 10.0 % 8.5 % 8.1 % 9.7 % 8.7 %

Zepzelca, Rylaze, Ziihera and Vyxeos are sold to customers through subsidiary specialty distributors of McKesson, Cencora, and Cardinal.

As of September 30, 2024, five customers accounted for 81% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 41% of gross accounts receivable, ASD Specialty Healthcare LLC, or ASD, which accounted for 14% of gross accounts receivable and McKesson Corporation and affiliates, or McKesson, which accounted for 14% of gross accounts receivable.

As of June 30, 2024, five customers accounted for 80% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 41% of gross accounts receivable, ASD Specialty Healthcare LLC, or ASD, which accounted for 13% of gross accounts receivable and McKesson Corporation and affiliates, or McKesson, which accounted for 11% of gross accounts receivable.

As of March 31, 2024, five customers accounted for 78% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 41% of gross accounts receivable, McKesson Corporation and affiliates, or McKesson, which accounted for 12% of gross accounts receivable and ASD Specialty Healthcare LLC, or ASD, which accounted for 12% of gross accounts receivable.

Cencora, Inc. 11 % 12 % 10 %

Cencora, Inc. (formerly AmerisourceBergen Corporation) 12 % 10 % 10 %

AmerisourceBergen Corporation 10 % 10 % 9 %

AmerisourceBergen Corporation 10 % 9 % 10 %

The Company recognized royalty revenue from distribution partners of $3,818,000 and $3,218,000 in the six months ended June 30, 2025 and 2024, respectively.Product sales to certain distribution partners that accounted for more than 10% of net product revenue for the three and six months ended June 30, 2025 and 2024 consists of the following: Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 McKesson 38% 38% 34% 43%Cardinal Health 27 18 22 19 INPHARMUS 10 — 15 — Cencora 11 11 13 17 SciClone 9 15 8 8 Revenue from product sales is recorded as net of applicable provisions for rebates, chargebacks, discounts, distribution-related fees and other sales-related deductions.

McKesson, Cardinal Health and Cencora accounted for 41%, 20% and 16%, respectively of the Company’s net product revenue for the year ended December 31, 2024.

The Company recognized royalty revenue from distribution partners of $4,351,000 and $3,814,000 in the nine months ended September 30, 2024 and 2023, respectively.Product sales to certain distribution partners that accounted for more than 10% of total product revenue, net, for the three and nine months ended September 30, 2024 and 2023 consists of the following: Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 McKesson 48% 48% 45% 45%Cardinal Health 21 14 20 13 Cencora 15 18 17 22 WEP — 15 3 9 As of September 30, 2024, the Company had recorded on the Consolidated Balance Sheets accounts receivable of approximately $19,916,000, of which $2,816,000 represents an unbilled portion to which the Company has unconditional rights to collect the consideration related to product sales to the Company’s distributor in Western Europe, WEP.Revenue from product sales is recorded as net of applicable provisions for rebates, chargebacks, discounts, distribution-related fees and other sales-related deductions.

McKesson, Cencora, WEP and Cardinal Health accounted for 46%, 22%, 10% and 13%, respectively, of the Company’s net product revenue for the year ended December 31, 2023.

McKesson, SciClone, AmerisourceBergen and Cardinal Health accounted for 46%, 20%, 18% and 12% respectively, of the Company’s product revenue, net, for the three months ended June 30, 2023.

McKesson, AmerisourceBergen, Cardinal Health, and WEP accounted for 45%, 29%, 13%, and 12%, respectively, of our gross product revenue for the three months ended March 31, 2023.

McKesson, AmerisourceBergen, and Cardinal Health accounted for 70.8%, 17.4%, and 10.1%, respectively, of our gross product revenue for the year ended December 31, 2022.

McKesson and AmerisourceBergen accounted for 78% and 14%, respectively, of the Company’s gross product revenue for the three months ended September 30, 2022.

McKesson, AmerisourceBergen and Cardinal Health accounted for 71%, 10% and 11%, respectively, of the Company’s product revenue, net, for the three months ended June 30, 2022.

McKesson, AmerisourceBergen, and Cardinal Health accounted for 60%, 25%, and 11%, respectively, of our gross product revenue for the three months ended March 31, 2022.

McKesson and AmerisourceBergen accounted for 73.2% and 17.6%, respectively, of our gross product revenue for the year ended December 31, 2021.

McKesson and AmerisourceBergen accounted for 66% and 24%, respectively, of the Company’s gross product revenue for the three months ended September 30, 2021.

As of December 31, 2024, three customers, BioCare, Healix Infusion Therapy, LLC (“Healix”) and Cencora, Inc. (f/k/a AmerisourceBergen Corporation), represented an aggregate of approximately 91% of our consolidated accounts receivable.

Our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc. and CVS Health Corporation, accounted for approximately 71%, 70% and 70% of total net sales of products for the years ended December 31, 2025, 2024 and 2023, respectively.

As of December 31, 2020, four customers exceeded the 10% threshold for outstanding receivables which were Indivior, AmerisourceBergen Corporation, Sunovion, and Cardinal Health Inc. which represented 53%, 14%, 13%, and 10%, respectively, of total trade and other receivables.

For example, for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta’s three largest distributors, together represented approximately 42% of Embecta’s worldwide gross sales.

ASD Specialty Healthcare LLC, which accounted for 37% of our gross accounts receivable;

Cencora, Inc. 47.5 % *

The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22%, 21% and 13%, respectively, of total accounts receivable at December 31, 2025.

The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 21%, 21% and 13%, respectively, of total accounts receivable at December 31, 2024.

The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 21%, 20% and 14%, respectively, of total accounts receivable at December 31, 2023.

The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately 21%, 20% and 13%, respectively, of total accounts receivable at December 31, 2022.

The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately 20%, 15% and 10%, respectively, of total accounts receivable at December 31, 2021.

The Company’s customers with the largest accounts receivable balances are McKesson Corporation and Cencora, Inc., which represented approximately 14% and 7%, respectively, of total gross accounts receivable at December 31, 2025.

Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 15% of our total product revenue in 2025 and collectively accounted for more than 76% of our total product revenue in 2025.

Each of our three major customers, Cencora, Inc., Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% of our total gross product sales and collectively accounted for more than 70% of our total gross product sales for the three months ended March 31, 2024 and 2023.

Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% of our total net product sales and collectively accounted for more than 75% of our total net product sales in 2023 and 2022.

Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 20% and 25% of our total net product sales and collectively accounted for more than 75% and 85% of our total net product sales in 2022 and 2021, respectively.

4571359638!SMALLPOX VACCINE

H-CORE THERAPEUTIC & VACCINE VENDOR MANAGED INVENTORY (VMI), DISTRIBUTION AND DESTRUCTION

DROSPIRENONE